Introduction (Part 2) - All-Trans Retinoic-Acid (ATRA) [Corrected 4].docx

**INTRODUCTION** **[2 All-Trans Retinoic-Acid (ATRA):]** The second chapter of the introduction will focus on the diverse significance of All-Trans Retinoic Acid (ATRA) in the field of cellular biology and therapeutic applications. **[2.1 General Overview and Properties of ATRA:]** All-trans Ret...

**INTRODUCTION** **[2 All-Trans Retinoic-Acid (ATRA):]** The second chapter of the introduction will focus on the diverse significance of All-Trans Retinoic Acid (ATRA) in the field of cellular biology and therapeutic applications. **[2.1 General Overview and Properties of ATRA:]** All-trans Retinoic Acid (ATRA) is a major metabolite of vitamin A and it plays an essential role in many biological processes. Indeed, Vitamin A, a fat-soluble vitamin, is important for human health since it supports vision, immune system function, and cellular homeostasis. Due to its unique chemical composition, ATRA inherits and improves these functions by deriving from vitamin A^1^. The activity of ATRA is determined by its molecular structure, which includes a β-ionone ring and a polyunsaturated side chain terminating in a carboxylic acid group. Due to its structure, ATRA binds specific nuclear receptors in the organism. These receptors are members of a large family of transcription factors that regulate gene expression. When ATRA interacts with these receptors, it regulates the transcription of genes involved in various physiological processes^2^. ATRA is also vital for vision. Indeed, vitamin A derivatives are essential for retinal health, especially for the production of rhodopsin, a pigment necessary for low-light vision. ATRA participates in cellular processes such as metabolism, regulating lipid metabolism, and energy balance^3^. Furthermore, ATRA is involved in cell proliferation and differentiation. This is especially evident in the context of skin health and epithelial tissue growth. ATRA contributes to the clearance of damaged or undesirable cells *via* apoptosis or programmed cell death, hence maintaining cell health and homeostasis^4^. The effects of ATRA are also related to embryonic development, which is critical to organ and tissue formation. Its regulatory function in gene expression throughout development is still being studied^5^. **[2.2 Metabolism of ATRA and Cellular Uptake:]** *2.2.1 Synthesis from Vitamin A* All-trans retinoic acid (ATRA) is formed from vitamin A through a sequence of metabolic steps. Retinol dehydrogenase catalyzes the conversion of retinol (vitamin A alcohol) into retinal (vitamin A aldehyde). This conversion to ATRA, also oxidizing the retina, is essential in converting vitamin A into a bioactive form that the body can use. Vitamin A to ATRA conversion is necessary for the action of molecules that regulate gene expression and it influences a number of physiological processes^1^. *2.2.2 Binding to Cellular Retinoic Acid-Binding Proteins (CRABPs)* After its generation, ATRA binds cellular proteins called retinoic acid-binding proteins (CRABPs). These proteins modulate the intracellular levels and action of ATRA. CRABPs monitor the level of ATRA in cells, thus allowing it to bind to nuclear receptors and hence inhibit the expression of certain genes. The interaction of ATRA with CRABPs governs two aspects controlling the biological activity of ATRA and this interaction is of relevance in cell differentiation and development, as well as other physiological activities^6^. *2.2.3 Oxidative Catabolism to Inactive Metabolites* ATRA metabolism is complicated, involving oxidative catabolism of inactive metabolites. This catabolic mechanism is critical for maintaining physiologically adequate amounts of ATRA in the body. The inactivation of ATRA ensures that its activity is closely controlled, limiting excessive accumulation and potential toxicity. The modulation of ATRA levels is critical for the proper control of a variety of biological processes, such as cell proliferation, differentiation, and apoptosis^7^. **[2.3 Mechanisms of Action in Cellular Processes:]** *2.3.1 Interaction with Nuclear Retinoid Receptors* All trans-retinoic Acid (ATRA) acts mainly through the interaction with nuclear retinoid receptors known as retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Three kinds of RARs (RARα, RARβ, and RARγ) and RXRs (RXRα, RXRβ, and RXRγ) are known, and they are products of distinct genes. ATRA requires all these receptors to control gene expression. They play essential roles in the regulation of genes involving cell development and differentiation, as well as apoptosis. Following the binding of these two types of receptors to ATRA, some events follow in a sequence that aims to modulate the transcriptional activity of the selected target genes. This modulation controls the action of ATRA in the context of cellular growth and in the process of programmed-cell-death/apoptosis. For ATRA to exert its function in cells, the compound must interact with RARs and RXRs. Additionally, RAR/RXR binding is crucial for ATRA\'s cancer therapy and developmental biology therapeutic applications^2^. *2.3.2 Regulation of Gene Expression via RARs* The interaction of ATRA with RARs is quite important in controlling gene activity. When activated by ATRA, these receptors can specifically bind to some DNA sequences, which are known as retinoic acid response elements (RAREs). Such binding initiates gene transcriptional changes, a vital ATRA-mediated biological regulatory mechanism. ATRA\'s ability to mediate gene expression by RARs underscores its fundamental roles in cell differentiation and death. Such processes are required for normal developmental physiology and exert profound effects upon pathologies such as cancer, where cell proliferation and death regulation are of vital importance^8^. *2.3.3 Involvement in Non-Genomic Signaling Pathways* ATRA regulates its genomic activities via non-genomic signaling pathways. Many specific signaling pathways, such as MAPK (Mitogen-Activated Protein Kinase) and PKA (Protein Kinase A) pathways have been implicated. This connection shows the range of ATRA activities, which goes beyond direct genomic pathways and entails a wider spectrum of cellular processes. These are non-genomic pathways important for ATRA\'s effect on cell signaling involving activities such as cell proliferation and survival. The involvement of ATRA in these molecular pathways supports the broad function of this compound in cellular biology, and it provides evidence of its role in several therapeutic contexts^9^. **[2.4 Role in Cellular Differentiation and Development:]** *2.4.1 Therapeutic Application in Acute Promyelocytic Leukemia (APL)* ATRA has been used in the treatment of a subtype of acute myeloid leukemia known as acute promyelocytic leukemia (APL). In APL, the administration of ATRA leads to differentiation induction in the leukemic cell. Following this differentiation is disease remission, and hence, differences in induction form a landmark for the treatment of disease^10^. In fact, the therapeutic action underlying this differentiating activity is the ability of ATRA to regulate the expression of genes involved in the development of hematopoietic cells. By affecting these genes, ATRA induces the differentiation and maturation of leukemic cells, limiting neoplastic cell replication, which results in clinical remission. This discovery has proved to be a significant development in cancer treatment, providing the first example of targeted therapy in the oncology field^11^. *2.4.2 Impact on Embryonic Development* Besides its use in cancer therapy, ATRA plays an important role in the process of embryonic development. With respect to this, ATRA controls and activates genes that are responsible for organ formation and tissue development. Indeed, ATRA-dependent regulation of cell differentiation contributes to embryonic development under the conditions of normal organ and tissue growth/maturation. This regulatory function is of great importance in normal development as well as in preventing the occurrence of developmental disorders. The latter function is entirely expected given the role that ATRA plays in embryonic development. The point emphasizes the importance of ATRA in developmental biology and the possible contribution of the retinoid in the design of therapeutic approaches to developmental disorders^12^. *2.4.3 Extending Beyond Hematopoietic Cells* It is known that the regulation of ATRA acts pervasively beyond the differentiation of hematopoietic cells. The regulatory effects exerted by the retinoid have been observed in many cell types and tissues, suggesting a broad action in cellular differentiation and development. ATRA\'s broad impact on diverse cell types demonstrates adaptability by a regulatory molecule in biological processes. However, given its potential to target many pathways and different cell types, ATRA is an appealing chemical not only in the treatment of leukemia but also in other applications such as tissue engineering, regenerative and developmental medicine^13^. **[2.5 ATRA Role in Solid Tumors:]** *2.5.1 Overview of ATRA in Solid Tumor Therapy* ATRA has been widely studied because of its importance in cell differentiation and death, as well as its therapeutic potential in solid tumors. Though ATRA is efficacious in acute promyelocytic leukemia (APL), its actions on solid tumors remain quite intricate and unclear. ATRA, either alone or combined with other therapeutic agents, has been studied in the treatment of solid cancers. However, ATRA-based therapies are not necessarily associated with strong anti-tumor responses. Hence, a larger number of studies is necessary for a better application of ATRA in the treatment of solid tumors^5^. *2.5.2 Mechanistic Insights into the Action of ATRA in Solid Tumors* ATRA is known to exert tumor-suppressive effects in epithelial tumor cells where regulation of RARβ2 expression through RARα takes place. Regulation of RARβ2 expression by ATRA is of extreme importance to direct malignant cells towards differentiation or self-destruction. Nevertheless, loss or repression of RARβ2 is a common event in a wide range of solid tumors, including head and neck, breast, lung, pancreatic, prostate, and cervical malignancies. In these types of cancers, the major mechanism of ATRA resistance is due to RARβ2 inactivation. Increased levels of corepressor and decreased levels of coactivator activities due to inadequate ATRA signaling and epigenetic modifications in the gene RARβ2 are known to cause resistance to the retinoid^5^. *2.5.3 Clinical Trials and Therapeutic Combinations* ATRA clinical trials in solid tumors, i.e., lung, mammary, and cervical cancer, have shown mixed results. Though in vitro and in vivo studies support an anti-tumor action of ATRA, definite therapeutic benefits do not emerge from the set of clinical trials performed^10^. This gap underlines the need for more research aimed at improving ATRA-based therapeutic efficacy through the design of innovative studies in the field of solid tumors. In some of the instances, especially in advanced non-small cell lung cancer, combined treatment of ATRA with other drugs such as paclitaxel and cisplatin resulted in better response rates as well as progression-free survival^5^. *2.5.4 ATRA and Resistance Mechanisms in Solid Tumors* In solid tumors, a major problem is represented by ATRA resistance. In fact, changes that lead to alteration in ligand-induced co-repressor release compared to the changes in co-activator recruitment modify ATRA anti-tumor efficacy. In addition, overexpression of some genes, genetic mutations, as well as epigenetic modifications, play a role in ATRA resistance. Understanding these pathways is critical for creating more effective ATRA-based treatments of solid tumors^5^. **[2.6 Therapeutic Implications and Limitations of ATRA:]** *2.6.1 Clinical Use Limitations* In terms of the broader therapeutic use of ATRA, one of the major limitations is represented by the short half-life of the compound in the human body. In fact, the short half-life and the rapid degradation of ATRA may be the basis for the inefficiency of the retinoid in the treatment of solid tumors. This is the result of the rapid metabolism and elimination of ATRA from the body, which makes it necessary to implement frequent dosing or high dosages of the retinoid to overcome potential side effects. Addressing these limitations would be essential in broadening the medical applications of ATRA^2^. *2.6.2 Research Efforts and Development of ATRA Analogues* The latest research efforts are aimed at increasing the half-life of ATRA and the design of combinations with other therapeutic drugs to augment the anti-cancer efficacy of the compound. A higher efficacy of ATRA in cancer treatment may be obtained with an increase in its bioavailability and anti-tumor activity through various approaches that include delivery methods such as improved formulations and combined therapies. In addition, the use of ATRA analogs is reported to result in positive outcomes as it reduces ATRA-associated toxicities. The pharmacokinetic advantages of these analogs increase drug efficiency and reduce adverse effects, enhancing the therapeutic potential of retinoids in cancer therapy^14^. **[BIBLIOGRAFIA:]** 1\. Lampen, A., Meyer, S., Arnhold, T. & Nau, H. Metabolism of vitamin A and its active metabolite all-trans-retinoic acid in small intestinal enterocytes. *J. Pharmacol. Exp. Ther.* **295**, 979--985 (2000).2. Siddikuzzaman, Guruvayoorappan, C. & Berlin Grace, V. M. All Trans Retinoic Acid and Cancer. *Immunopharmacol. Immunotoxicol.* **33**, 241--249 (2011).3. Xia, Q.-Q., Zhang, L.-M., Zhou, Y.-Y., Wu, Y.-L. & Li, J. All-trans-retinoic acid generation is an antidotal clearance pathway for all-trans-retinal in the retina. *J. Zhejiang Univ. Sci. B* **20**, 960--971 (2019).4. Axel, D. I. *et al.* All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells. *Cardiovasc. Res.* **49**, 851--862 (2001).5. Ni, X., Hu, G. & Cai, X. The success and the challenge of all-trans retinoic acid in the treatment of cancer. *Crit. Rev. Food Sci. Nutr.* **59**, S71--S80 (2019).6. Nagpal, I. & Wei, L.-N. All-trans Retinoic Acid as a Versatile Cytosolic Signal Modulator Mediated by CRABP1. *Int. J. Mol. Sci.* **20**, 3610 (2019).7. Napoli, J. L. Physiological insights into all-trans-retinoic acid biosynthesis. *Biochim. Biophys. Acta* **1821**, 152--167 (2012).8. Szymański, Ł. *et al.* Retinoic Acid and Its Derivatives in Skin. *Cells* **9**, 2660 (2020).9. Nhieu, J., Lin, Y.-L. & Wei, L.-N. Noncanonical retinoic acid signaling. *Methods Enzymol.* **637**, 261--281 (2020).10. Garattini, E. *et al.* Retinoids and breast cancer: From basic studies to the clinic and back again. *Cancer Treat. Rev.* **40**, 739--749 (2014).11. Degos, L. & Wang, Z. Y. All trans retinoic acid in acute promyelocytic leukemia. *Oncogene* **20**, 7140--7145 (2001).12. Chen, J. & Li, Q. Implication of retinoic acid receptor selective signaling in myogenic differentiation. *Sci. Rep.* **6**, 18856 (2016).13. Brown, G. Retinoic acid receptor regulation of decision-making for cell differentiation. *Front. Cell Dev. Biol.* **11**, 1182204 (2023).14. Liang, C. *et al.* Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia. *Eur. J. Med. Chem.* **220**, 113451 (2021).